Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

TB among aboriginal Canadians

Leo M. Kahana
CMAJ May 16, 2000 162 (10) 1404;
Leo M. Kahana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Correction - June 27, 2000

The review by Mark FitzGerald and coworkers on the control of tuberculosis in aboriginal Canadians1 would have been improved by a brief reference to the history of the disease among these first Canadians. Tuberculosis was recognized in aboriginal North Americans in the pre-Columbian period but only became a major problem in the latter part of the 19th century, after we and the Americans had destroyed their livelihood, impoverished them and crowded them together on reservations or in prison (as we still do).2 Ferguson reported a mortality rate of 9000 per 100 000 in 1886, which is the highest rate ever recorded.3 For treatment we sent aboriginal people to fill the beds of sanatoria in southern Canada, where many died. When their families came to see what had happened to them, even their graves couldn't be located.

In view of the increased incidence of tuberculosis in aboriginal populations, it is natural to consider preventive methods. Bacillus Calmette-Guérin vaccine has been administered to more than 3 billion people, but there remains considerable doubt that it accomplishes anything. In controlled studies the protective efficacy varies from 57% to more than 75%, and it is not clear that averaging such disparate results by meta-analysis is of any significance.4 The efficacy is not, as the authors state, proven, and there is no reason to continue its wide use in aboriginal infants in contrast to the practice in the white population. Isoniazid prophylaxis in infected individuals is undoubtedly effective, but there has to be considerable caution in administering it to a population in which alcoholism and viral hepatitis are problems. The incidence of hepatotoxicity may be small, but the results can be catastrophic.[5, 6] A better alternative to isoniazid might be a combination of rifampin and levofloxacin, with a minimal risk of hepatitis.

The authors worry, perhaps patronizingly, about the risks of "health transfer" - allowing aboriginal people to take over responsibility for their own health needs. Our record, at least where tuberculosis is concerned, is dismal. The best solution would be to facilitate the transfer process and provide aboriginal people with their own clinics, nurses and doctors.

References

  1. 1.↵
    FitzGerald JM, Wang L, Elwood RK. Tuberculosis: 13. Control of the disease among aboriginal people in Canada. CMAJ 2000;162(3):351-5.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Daniel TM, Bates JH, Downes KA. History of tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington: ASM Press; 1994. p. 13-24.
  3. 3.↵
    Ferguson RG. Studies in tuberculosis. Toronto: University of Toronto Press; 1955. p. 6.
  4. 4.↵
    Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and controls. Washington: ASM Press; 1994. p. 531-57.
  5. 5.↵
    Kahana LM. Hepatotoxicity of antituberculosis drugs [letter]. Thorax 1996;51:873.
    OpenUrlFREE Full Text
  6. 6.↵
    Mitchell L, Wendon J, Fitt S, Williams R. Anti-tuberculous therapy and acute liver failure. Lancet 1995;345:555-6.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 162, Issue 10
16 May 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
TB among aboriginal Canadians
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
TB among aboriginal Canadians
Leo M. Kahana
CMAJ May 2000, 162 (10) 1404;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
TB among aboriginal Canadians
Leo M. Kahana
CMAJ May 2000, 162 (10) 1404;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Correction
  • PubMed
  • Google Scholar

Cited By...

  • Correction
  • Google Scholar

More in this TOC Section

  • Hospital-at-home programs in Canada: challenges and pitfalls
  • Author response to “Pitfalls of analyzing perinatal outcomes by health care provider”
  • Pitfalls of analyzing perinatal outcomes by health care provider
Show more Letters

Similar Articles

Collections

  • Topics
    • Drugs: immunologic
    • History of medicine
    • Indigenous health
    • Infectious diseases
    • Patient education

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire